Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep;9(18):1447. doi: 10.21037/atm-21-3928

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Annals of Translational Medicine. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

TIM3 blockade slows OS tumor progression in vivo. (A) Schematic representation of OS xenograft experiment. BALB/c nude mice were injected with 143B cells stably expressing firefly luciferase into the lateral tail vein. Mice either received i.p. injection of isotype control or anti-mouse TIM-3 antibody (clone B8.2C12) after tumor cell inoculation. Tumors were imaged live in vivo (B,C). Shown are images at the end of 4 weeks (n=10/group). (D) Change in bodyweight of mice in the different experimental groups over 4 weeks (n=5/group). (E) Tumor growth rate in the two experimental groups (n=5/group). TIM3, T cell immunoglobulin and mucin-domain containing 3; OS, osteosarcoma. *, P<0.05; ***, P<0.001.